revenu beat driven cf strength ep beat
also advanc phiii cf tripl data earli
remain next key catalyst
ep beat revenu beat vs con
product level cf consensu figur hard compar given orkambi
guidanc includ kalydeco orkambi symdeko full-
year non-gaap combin sg expens
updat management announc initi two phiii
studi one studi het/min popul
second studi homozygot phiii studi
homozyg patient base newli announc phii data releas today
four week treatment led increment
mean absolut improv ppfev patient alreadi receiv
tezacaftor/ivacaftor compani also announc phii data once-
daili kalydeco tezacaftor next-gen corrector het/min patient tripl
combin next-gen corrector respect
base tripl therapi led mean absolut ppfev improv
four week treatment management plan conduct addit dose-
rang work bridg work done subsequ
futur explor potenti qd tripl regimen addit work
complet request fda
 unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
takeaway call symdeko volum driven kalydeco
orkambi experienc patient well treatment nave patient
patient treat date
incid sever rash low seriou event rash
resolv discontinu treatment patient re-
challeng without new rash slight channel build symdeko
off-set channel declin orkambi kalydeco
total cf product revenu accur reflect product demand
busi develop management note prefer early-stag high scienc
collabor previous enter crispr
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
cover vs larg scale management note cf revenu
guidanc assum sale growth driven primarili market
three therapi orkambi/kalydeco/symdeko current
reimburs patient growth primarili driven
start year slower once-daili major neg overal
quarter clean strong revenu growth increas estim
toward high-end management rang given broad perform across
therapi two cf tripl phiii strong financi momentum
continu see well posit slowdown once-daili
develop disappoint like set much higher competit bar
long-term posit see bid vs qd regimen
impact uptak tripl thu qd regimen import life-cycle
strategi timelin less import
triplet approv
triplet approv uptak life-cycl manag oper margin drive
uptak life-cycl manag oper margin drive
penetr across cf medicin life-cycl extens extend
franchis bull case assum higher penetr tripl
therapi het/min homozygot patient initi tripl data
replic phiii therapi launch ww sale
het/min homozygot addit tripl data commerci
success key
risk-adjust tripl combo success mainten key cf franchis
life-cycl extens base case assum penetr orkambi
homozyg cf patient eventu switch captur
homozyg het/min market tripl combo risk-adjust peak ww sale
tripl combin therapi
modest orkambi uptak tripl combin fail achiev approv
het/min popul bear case assum row us
penetr orkambi homozyg cf patient peak ww sale
kalydeco monotherapi peak
overweight vertex believ
initi tripl data replic phiii
studi see vertex clear leader
cf therapi beliv management potenti
deliv ep overtim
initi phi phii data tripl
het/min popul better
kalydeco-lin efficaci
homozyg popul thu includ
risk-adjust tripl combin revenu
base case
believ potenti
competit believ vertex
signific advantag posit
on-market doubl combin in-
share competitor long-
main driver vertex phiii
tripl studi time approv launch
uptak current therapi
orkambi/kalydeco/symdeko uptak
risk achiev price
combo penetr fall short
kalydeco/orkambi/symdeko sale fail
meet expect
data clinic candid
tripl combin fail meet expect
data competit exce
inform opinion research prepar co llc and/or and/or morgan
stanley mexico de bolsa de and/or canada limit use disclosur section includ morgan
stanley co llc mexico de bolsa de canada limit affili
necessari
import disclosur stock price chart equiti rate histori regard compani subject report pleas see morgan
stanley research disclosur websit www morganstanley com/researchdisclosur contact invest repres
research broadway attent research manag new york ny usa
valuat methodolog risk associ recommend rate price target referenc research report pleas contact client
support follow us/canada hong kong latin america london
singapor sydney tokyo altern may contact invest repres morgan
stanley research broadway attent research manag new york ny usa
follow analyst herebi certifi view compani secur discuss report accur express
receiv receiv direct indirect compens exchang express specif recommend view report matthew
unless otherwis state individu list cover page report research analyst
morgan stanley research publish accord conflict manag polici avail
import us regulatori disclosur subject compani
march benefici own class common equiti secur follow compani cover morgan
within last month manag co-manag public offer offer secur amgen inc beigen ltd biohaven
within last month receiv compens invest bank servic amgen inc beigen ltd biohaven
next month expect receiv intend seek compens invest bank servic
within last month receiv compens product servic invest bank servic amgen inc
within last month provid provid invest bank servic invest bank client relationship
follow compani amgen inc beigen ltd biogen inc biohaven
within last month either provid provid non-invest bank securities-rel servic and/or past
enter agreement provid servic client relationship follow compani amgen inc biogen inc
 co llc make market secur amgen inc
equiti research analyst strategist princip respons prepar research receiv compens base upon
variou factor includ qualiti research investor client feedback stock pick competit factor firm revenu overal invest bank
revenu equiti research analyst strategist compens link invest bank capit market transact perform morgan
stanley profit revenu particular trade desk
affili busi relat companies/instru cover research includ market make provid
liquid fund manag commerci bank extens credit invest servic invest bank sell buy
custom securities/instru compani cover research princip basi may posit debt
compani instrument discuss report trade may trade princip debt secur relat deriv
subject debt research report
certain disclosur list also complianc applic regul non-u jurisdict
